| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ABCC13 |
| Uniprot No | Q9NSE7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-274aa |
| 氨基酸序列 | MLSSTQNAGGSYQRVRGALDTQKCSPEKSASFFSKVTYSWFSRVITLGYKRPLEREDLFE LKESDSFCTACPIFEKQWRKEVLRNQERQKVKVSCYKEAHIKKPSLLYALWNTFKSILIQ VALFKVFADILSFTSPLIMKQIIIFCEHSSDFGWNGYGYAVALLVVVFLQTLILQQYQRF NMLTSAKVKTAVNGLIYKKALLLSNVSRQKFSTGEIINLMSATHGLDSKPQSPLVCPFSN PNGRISPLARAGSSSVSRGGSPCVCYTNKCFSCN |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ABCC13重组蛋白的参考文献示例(注：部分文献为假设性示例，实际文献需通过学术数据库验证)：
---
1. **文献名称**：*ABCC13 Expression in Hepatocellular Carcinoma and Its Role in Chemotherapy Resistance*
**作者**：Zhang S. et al.
**摘要**：研究揭示了ABCC13在肝癌组织中的高表达现象，并通过重组蛋白体外实验证实其过表达与化疗药物外排及耐药性相关，提示ABCC13可能作为潜在治疗靶点。
2. **文献名称**：*Cloning and Functional Characterization of Recombinant ABCC13 in Mammalian Cells*
**作者**：Li W. et al.
**摘要**：成功克隆ABCC13基因并在HEK293细胞中表达重组蛋白，证实其具备ATP依赖的转运活性，为后续研究其底物特异性及生理功能奠定基础。
3. **文献名称**：*Substrate Specificity of ABCC13 Recombinant Protein in Drug Transport*
**作者**：Wang X. et al.
**摘要**：通过体外膜转运实验，利用重组ABCC13蛋白筛选多种抗癌药物及代谢产物，发现其对特定蒽环类药物具有显著转运能力，提示其在个体化用药中的潜在价值。
4. **文献名称**：*Genetic Variants of ABCC13 Alter Drug Metabolism via Recombinant Protein Activity Assays*
**作者**：Chen L. et al.
**摘要**：分析ABCC13基因多态性对功能的影响，通过重组突变体蛋白表达实验，发现某些单核苷酸变异(SNPs)显著降低其转运效率，可能与个体药物反应差异相关。
---
**建议**：上述文献为示例性质，实际研究中请通过PubMed、Web of Science等平台以关键词“ABCC13 recombinant protein”检索最新文献，并优先选择近5年发表的高影响力期刊论文。
**Background of ABCC13 Recombinant Protein**
ABCC13 (ATP-binding cassette subfamily C member 13) is a member of the ABC transporter superfamily, which plays critical roles in cellular transport processes, including drug resistance, lipid trafficking, and ion channel regulation. Although less characterized compared to other ABC proteins like ABCC1 (MRP1) or ABCB1 (P-glycoprotein), ABCC13 is hypothesized to function as an efflux transporter, potentially influencing the pharmacokinetics of endogenous compounds or xenobiotics. The gene encoding ABCC13 is located on human chromosome 21 and exhibits tissue-specific expression, with higher levels detected in the liver, testis, and gastrointestinal tract.
Structurally, ABCC13 contains conserved ABC transporter domains: two nucleotide-binding domains (NBDs) that hydrolyze ATP and transmembrane domains (TMDs) involved in substrate recognition and translocation. However, its exact physiological substrates and regulatory mechanisms remain poorly understood. Research suggests ABCC13 may have evolutionary significance, as pseudogenization (loss of function) occurs in some populations, hinting at possible adaptive roles in human evolution.
Recombinant ABCC13 protein is produced using heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to enable functional and structural studies. Its recombinant form allows researchers to investigate substrate specificity, ATPase activity, and interactions with pharmacological agents. Studies leveraging ABCC13 recombinant protein aim to clarify its role in disease contexts, such as cancer multidrug resistance or metabolic disorders, and explore its potential as a therapeutic target or biomarker. Despite limited data, advancing ABCC13 research could deepen insights into ABC transporter biology and its implications for precision medicine.
×
